Hematology

Oral azacitidine had a similar safety profile across the 200-mg and 300-mg groups in lower- to intermediate-risk MDS.

The FDA granted an approval to imetelstat for certain patients with low- to intermediate-1-risk MDS who have transfusion-dependent anemia.

Oncology nurses can aid in the identification and management of oral adverse effects from cancer therapies.

Triplet therapies containing belantamab mafodotin, pomalidomide, and dexamethasone may address an unmet need for relapsed/refractory multiple myeloma.

Updated data from the MANIFEST-2 study support a paradigm shift in the treatment of JAK inhibitor–naive patients with myelofibrosis.

A brentuximab vedotin-containing regimen led to “unprecedented” progression-free survival improvements in patients with advanced classical Hodgkin lymphoma.

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase inhibitors for Ph-positive chronic phase chronic myeloid leukemia.

This marks the only CAR T-cell therapy approved by the FDA for 4 subtypes of non-Hodgkin lymphoma.

Oncology nurses can educate patients about the availability of pre-exposure prophylaxis for preventing COVID-19.

Uproleselan plus chemotherapy missed the overall survival end point in the phase 3 trial assessing the combination in patients with relapsed/refractory acute myeloid leukemia.

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lisocabtagene maraleucel was approved by the FDA to treat adults with relapsed/refractory follicular lymphoma who were treated with 2 or more prior lines of systemic therapy.

Recent data from a phase 3b trial support venetoclax as a CLL treatment option for those with or without B-cell receptor–associated kinase inhibitor treatment.

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.

Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.

Nurse coordinators should aim to transmit information to both the patient and caregiver during outpatient CAR T-cell treatment process.

Encouraging responses were observed in most patients with relapsed/refractory follicular lymphoma treated with loncastuximab tesirine and rituximab.

All patients treated with CAR T-cell products are recommended to be monitored life-long for the risk of secondary malignancy, according to the FDA.

Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.

The FDA granted tamibarotene plus azacitidine and venetoclax fast track designation for the treatment of newly diagnosed, unfit, RARA-overexpressed AML.

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

The FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.

Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.

Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.

The new drug application for revumenib is supported by data from the AUGMENT-101 trial of patients with KMT2A-rearranged acute myeloid leukemia or acute lymphoblastic leukemia.

Progression-free and overall survival benefits were obtained with MRD-guided ibrutinib plus venetoclax when compared with fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

Venetoclax provided long-lasting responses in patients with relapsed/refractory chronic lymphocytic leukemia.

The benefits of imetelstat outweigh the risks for anemia treatment in lower-risk myelodysplastic syndrome, according to a vote by the FDA’s Oncologic Drugs Advisory Committee.

Accelerated approval has been granted by the FDA to lisocabtagene maraleucel for the treatment of certain patients with relapsed/refractory CLL or SLL.